Retreatment with anti-PD-1 antibody in non-small cell lung cancer patients previously treated with anti-PD-L1 antibody.

Abstract:

BACKGROUND:This study evaluated the efficacy and safety of retreatment with anti-programmed death 1 (anti-PD-1) antibodies in patients with advanced non-small cell lung cancer (NSCLC) after prior treatment with anti-programmed death-ligand 1 (anti-PD-L1) antibodies. METHODS:Data (N = 15) on patients' characteristics, number of cycles, regimens, their best response and immune-related adverse events (irAEs) were recorded retrospectively. RESULTS:NSCLC was initially treated with anti-PD-L1 antibody atezolizumab (N = 14) or durvalumab (N = 1). No patients had a high (≥50%) tumor expression of PD-L1. The median cycles for atezolizumab were five (range 1-15), and median progression-free survival was 2.8 and 6.0 months for atezolizumab and durvalumab, respectively. Five (33.3%) and nine (60.0%) patients showed stable and progressive disease as their best response, respectively. No differences in irAEs between anti-PD-L1 and anti-PD-1 antibodies occurred. CONCLUSION:Patients treated with anti-PD-L1 antibodies for NSCLC received limited benefits from retreatment with anti-PD-1 antibodies.

journal_name

Thorac Cancer

journal_title

Thoracic cancer

authors

Fujita K,Yamamoto Y,Kanai O,Okamura M,Hashimoto M,Nakatani K,Sawai S,Mio T

doi

10.1111/1759-7714.13241

subject

Has Abstract

pub_date

2020-01-01 00:00:00

pages

15-18

issue

1

eissn

1759-7706

issn

1759-7714

journal_volume

11

pub_type

杂志文章
  • Micro ribonucleic acid-93 promotes proliferation and migration of esophageal squamous cell carcinoma by targeting disabled 2.

    abstract:BACKGROUND:Accumulated evidence has revealed that the dysregulation of micro ribonucleic acids (miRNAs) may contribute to esophageal squamous cell carcinoma (ESCC). MiR-93, which is a member of the miRNA cluster miR-106b∼25, has been widely studied for its tumor promoting effect on different types of cancers. However, ...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12242

    authors: Li C,Ding C,Chen T,Chen J,Xu Z,Lei Z,Xu C,Zhao J

    更新日期:2015-07-01 00:00:00

  • Association of Chlamydia pneumoniae immunoglobulin G antibodies with the risk of lung cancer among non-smoking women in Liaoning, China.

    abstract::The role of Chlamydia pneumoniae in the cause of lung cancer is controversial. In this study, we investigated the association between C. pneumoniae immunoglobulin (Ig) G antibodies and risk of lung cancer among non-smoking women. C. pneumoniae IgG antibody levels were compared between 192 adult Chinese women who met t...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/j.1759-7714.2010.00021.x

    authors: Liu Z,Su M,Yu SC,Yin ZH,Zhou BS

    更新日期:2010-09-01 00:00:00

  • Primary inflammatory myofibroblastic tumor of the diaphragm: Report of a case.

    abstract::We report a case of primary inflammatory myofibroblastic tumor of the diaphragm in a 64-year-old man. The patient was hospitalized for a computed tomography (CT)-detected large tissue mass at the left lower lung field. Complete tumor excision followed by pathological investigation was performed. Microscopically, the t...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/j.1759-7714.2012.00155.x

    authors: Fu J,Wu Q,Zhang Y,Zhang X,Wang Z

    更新日期:2013-11-01 00:00:00

  • Gefitinib versus erlotinib as salvage treatment for lung adenocarcinoma patients who benefited from the initial gefitinib: A retrospective study.

    abstract:BACKGROUND:  The optimal strategy was not established for patients who initially responded to gefitinib although re-administration of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) has been proven to be an option. Gefitinib and erlotinib were compared as salvage treatment after gefitinib fail...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/j.1759-7714.2012.00152.x

    authors: Yu S,Wang Y,Li J,Hao X,Wang B,Wang Z,Zhang X,Shi Y

    更新日期:2013-05-01 00:00:00

  • Body mass index and exon 19 mutation as factors predicting the therapeutic efficacy of gefitinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer.

    abstract:BACKGROUND:Many randomized clinical trials have demonstrated that epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are advantageous over standard chemotherapy, either as front-line treatment or as further management of patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC). Howev...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12275

    authors: Sun H,Sun X,Zhai X,Guo J,Liu Y,Ying J,Wang Z

    更新日期:2016-01-01 00:00:00

  • Lung adenocarcinoma in a patient with a cis EGFR L858R-K860I doublet mutation identified using NGS-based profiling test: Negative diagnosis on initial companion test and successful treatment with osimertinib.

    abstract::Tyrosine kinase inhibitors are used as first-line treatment for non-small cell lung cancer (NSCLC) patients harboring driver mutations in EGFR, ALK, ROS1, and BRAF. Currently, standard molecular testing approaches help identify single genes for such targetable driver mutations in NSCLC; however, next-generation sequen...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.13694

    authors: Onozawa H,Saito H,Sunami K,Kubo T,Yamamoto N,Kasajima R,Ohtsu T,Hiroshima Y,Kanamori H,Yokose T,Miyagi Y

    更新日期:2020-12-01 00:00:00

  • Alteration in gene expression profiles of thymoma: Genetic differences and potential novel targets.

    abstract:BACKGROUND:This study was conducted to investigate the gene expression profiles associated with thymoma to better understand the molecular mechanism underlying the pathogenesis of thymoma. METHODS:Eight patients with thymomas (type A, AB, B1, and B2) and four controls with thymic cysts were analyzed using microarray p...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13053

    authors: Meng FJ,Wang S,Zhang J,Yan YJ,Wang CY,Yang CR,Guan ZY,Wang CL

    更新日期:2019-05-01 00:00:00

  • Validated LC-MS/MS method of Sphingosine 1-phosphate quantification in human serum for evaluation of response to radiotherapy in lung cancer.

    abstract:BACKGROUND:Sphingosine 1-phosphate (S1P), a bioactive lipid, has been shown to mediate cancer processes. Therefore, accurate qualitative and quantitative determination is essential. The current assay method is still cumbersome to be of practical use worldwide and the aim of this study was therefore to develop a fast, a...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13409

    authors: Tang X,Chen H,Chen G,Duan C,Fan Q,Li H,Wang Y,Li Z,Shi W,Liu Y

    更新日期:2020-06-01 00:00:00

  • Drastic healing process after pembrolizumab monotherapy in a case of advanced squamous cell carcinoma with severe bronchial stenosis observed over a two-year period using continuous bronchoscopy: A case report.

    abstract::Programmed cell death-1 immune checkpoint inhibitor (ICI) antibody has proven to be effective in advanced non-small cell lung cancer (NSCLC) patients positive for programmed cell death-1 ligand-1. However, there are currently no reports which evaluate drug efficacy by continuous bronchoscopic observation. A 75-year-ol...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.13390

    authors: Morikawa K,Kida H,Handa H,Inoue T,Miyazawa T,Mineshita M

    更新日期:2020-05-01 00:00:00

  • Elevated pretreatment neutrophil/white blood cell ratio and monocyte/lymphocyte ratio predict poor survival in patients with curatively resected non-small cell lung cancer: Results from a large cohort.

    abstract:BACKGROUND:The prognostic values of preoperative neutrophil/lymphocyte ratio (NLR), monocyte/lymphocyte ratio (MLR), and platelet/lymphocyte ratio (PLR) in non-small cell lung cancer (NSCLC) have been previously described. This study assessed the prognostic values of other pretreatment complete blood cell parameters in...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12454

    authors: Yuan C,Li N,Mao X,Liu Z,Ou W,Wang SY

    更新日期:2017-07-01 00:00:00

  • Thoracoscopic completion right lower lobectomy after anteromedial basilar segmentectomy in early-stage lung cancer.

    abstract::This report describes the surgical management of a male patient with early-stage lung cancer who underwent thoracoscopic completion right lower lobectomy after previously undergoing sublobar resection for multifocal ground glass nodules of the lung. Perioperative considerations associated with the management of dense ...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.13036

    authors: Liu YW,Chou SH,Hung JY,Kao CN,Chang PC

    更新日期:2019-05-01 00:00:00

  • Intercostal hemangioma presenting with multiple metastasized lung nodules caused by pneumonia.

    abstract::Multiple lung nodules caused by pneumonia are a rare presentation in intercostal hemangioma. We experienced a case with intercostal hemangioma that presented with multiple metastasized lung nodules caused by pneumonia, which had previously been misdiagnosed as sarcoma six months earlier. The patient was treated for pn...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/j.1759-7714.2010.00024.x

    authors: Mei L,Shi H,Che G

    更新日期:2010-11-01 00:00:00

  • Association of CD8 T cell apoptosis and EGFR mutation in non-small lung cancer patients.

    abstract:BACKGROUND:The abundance of tumor infiltrating CD8 T cells is an important parameter for antitumor effect of PD-1/PD-L1 immune checkpoint inhibitors, which is less in epidermal growth factor receptor (EGFR) mutation than wild-type non-small cell lung cancer (NSCLC). The mechanism still requires further study. METHODS:...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13504

    authors: Zhao C,Su C,Li X,Zhou C

    更新日期:2020-08-01 00:00:00

  • Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancer.

    abstract:BACKGROUND:ALK-tyrosine kinase inhibitors (TKIs) have been proven effective for treating ALK-positive non-small cell lung cancer (NSCLC), although patients present with variable responses and disease progression courses. The detailed underlying molecular mechanisms require further investigation to yield a better progno...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12791

    authors: Kang J,Chen HJ,Zhang XC,Su J,Zhou Q,Tu HY,Wang Z,Wang BC,Zhong WZ,Yang XN,Chen ZH,Ding Y,Wu X,Wang M,Fu JG,Yang Z,Zhang X,Shao YW,Wu YL,Yang JJ

    更新日期:2018-09-01 00:00:00

  • Survival analysis via nomogram of surgical patients with malignant pleural mesothelioma in the Surveillance, Epidemiology, and End Results database.

    abstract:BACKGROUND:Malignant pleural mesothelioma (MPM) is a rare but aggressive tumor that originates from the pleura and has a poor prognosis. Eligible patients can benefit from surgery, but their survival is affected by many factors. Therefore, we created a graphic model that could predict the prognosis of surgically treate...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13063

    authors: Zhuo M,Zheng Q,Chi Y,Jia B,Zhao J,Wu M,An T,Wang Y,Li J,Zhao X,Yang X,Zhong J,Chen H,Dong Z,Wang J,Zhai X,Wang Z

    更新日期:2019-05-01 00:00:00

  • Case report of apatinib mesylate treatment in rare advanced tracheal adenoid cystic carcinoma.

    abstract::A 57-year-old man was admitted to our department 10 years ago, diagnosed with tracheal adenoid cystic carcinoma. After discontinuing chemotherapy and radiotherapy, the disease recurred in December 2016. Apatinib mesylate (500 mg/day) was administered and computed tomography revealed that his symptoms were significantl...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.12506

    authors: Wang H

    更新日期:2017-11-01 00:00:00

  • Experience with the "da Vinci" robotic system for early-stage thymomas: Report of 23 cases.

    abstract:BACKGROUND:The aim of this study was to report a single referral center experience in robotic extended thymectomy for clinical early stage thymomas, evaluating its safety, feasibility and efficacy, with special regard to oncological outcomes. METHODS:Between January 2009 and December 2012, we retrospectively selected ...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12097

    authors: Huang P,Ye B,Yang Y,Tantai JC,Zhao H

    更新日期:2014-07-01 00:00:00

  • Intensity of SLX predicts distance of tumor spread through alveolar spaces in stage I lung adenocarcinoma.

    abstract:BACKGROUND:Tumor spread through alveolar spaces (STAS) is a recently described invasive pattern associated with the prognosis and recurrence of lung adenocarcinoma. This study was performed to determine whether the presence and distance of STAS can be predicted by the immunohistochemical intensity of SLX, a well-known ...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13008

    authors: Hara K,Mizuguchi S,Okada S,Izumi N,Tsukioka T,Komatsu H,Ohsawa M,Inaba M,Shibata T,Nishiyama N

    更新日期:2019-04-01 00:00:00

  • Bronchomediastinal fistula detected accidently during palliative radiation therapy.

    abstract::Bronchomediastinal fistula is an extremely rare complication resulting from diseases such as mediastinitis or mediastinal malignancies. In patients with lung cancer, bronchomediastinal fistula formation has rarely been reported, except during post-chemotherapy or post-radiation therapy complications. An 84-year-old vi...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/j.1759-7714.2012.00167.x

    authors: Song SH,Oh YJ,Chae SM,Lee J

    更新日期:2013-08-01 00:00:00

  • Prognostic role of Rab27A and Rab27B expression in patients with non-small cell lung carcinoma.

    abstract:BACKGROUND:Rab27A and Rab27B are the major components of vesicle fusion and trafficking in exosome secretion and play important roles in tumor progression and metastasis. In addition, Rab27A and Rab27B are associated with tumor prognosis. This study investigated the prognostic roles of Rab27A and Rab27B expression in p...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12919

    authors: Koh HM,Song DH

    更新日期:2019-02-01 00:00:00

  • Feasibility of re-biopsy and EGFR mutation analysis in patients with non-small cell lung cancer.

    abstract:BACKGROUND:In cases of EGFR-tyrosine kinase inhibitor (TKI) failure, re-biopsy may be useful to understand resistance mechanisms and guide further treatment decisions. However, performing re-biopsy is challenging because of several hurdles. We assessed the feasibility of re-biopsy in advanced non-small cell lung cancer...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12762

    authors: Kim TO,Oh IJ,Kho BG,Park HY,Chang JS,Park CK,Shin HJ,Lim JH,Kwon YS,Kim YI,Lim SC,Kim YC,Choi YD

    更新日期:2018-07-01 00:00:00

  • Radical thoracic radiotherapy may provide favorable outcomes for stage IV non-small cell lung cancer.

    abstract:BACKGROUND:This study investigates the outcome of synchronous stage IV non-small cell lung cancer (NSCLC) patients who received radical thoracic radiotherapy (TRT). METHODS:We retrospectively reviewed the charts of stage IV NSCLC patients treated with TRT between January 2007 and December 2011. Radiotherapy was consid...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12305

    authors: Wang J,Ji Z,Wang X,Liang J,Hui Z,Lv J,Zhou Z,Yin W,Wang L

    更新日期:2016-03-01 00:00:00

  • Secondary biopsy of non-oncogenic-driven lung cancer may reveal a clinically sensible histologic change. A brief report of two paradigmatic cases.

    abstract::After an initial benefit, non-small-cell lung cancer (NSCLC) patients receiving therapy with tyrosine kinase inhibitors develop drug resistance through a variety of mechanisms. Among these, tumor histology changes are a mechanism of acquired resistance in epidermal growth factor receptor-mutated and anaplastic lymphom...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.12416

    authors: Mengoli MC,Orsi G,Lococo F,Grizzi G,Barbieri F,Bertolini F,Rossi G,Novello S

    更新日期:2017-07-01 00:00:00

  • A case of huge esophageal carcinosarcoma.

    abstract::Carcinosarcoma of the esophagus is a rare malignant neoplasm with both epithelial and mesenchymal (sarcomatous) components. We describe a case of a 72-year-old man with a huge esophageal tumor which could often have been considered inoperable. However, the patient underwent a curative resection and had a good prognosi...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/j.1759-7714.2011.00069.x

    authors: Hu M,Zhi XY,Sun KL

    更新日期:2011-11-01 00:00:00

  • Male breast cancer: A closer look at patient and tumor characteristics and factors associated with survival.

    abstract:BACKGROUND:The prognostic effect of molecular subtypes on male breast cancer (MBC) remains unclear. The aim of this study was to evaluate the clinicopathological and prognostic factors of MBC patients. METHODS:From 1 January 1990 to 31 December 2014, the data of 152 MBC and 304 female breast cancer (FBC) patients were...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13611

    authors: Zhao J,Wang B,Zhao J,Mao Y,Liu J,Yang Y

    更新日期:2020-11-01 00:00:00

  • Abscopal effect induced by modulated radiation therapy and pembrolizumab in a patient with pancreatic metastatic lung squamous cell carcinoma.

    abstract::The main recurrence pattern for lung cancer patients after radical surgery is distant metastasis. The probability of pancreatic metastasis in patients diagnosed with lung squamous cell carcinoma is 0.02%, with a poor prognosis. Chemotherapy is the preferred treatment for recurrence. Single lesions or oligometastasis c...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.13427

    authors: Wang W,Huang C,Wu S,Liu Z,Liu L,Li L,Li S

    更新日期:2020-07-01 00:00:00

  • Efficacy of combined icotinib and pemetrexed in EGFR mutant lung adenocarcinoma cell line xenografts.

    abstract:BACKGROUND:The combination of EGFR tyrosine kinase inhibitors (TKIs) and chemotherapy is thought to increase treatment efficacy in non-small-cell lung cancer (NSCLC). This study investigated the efficacy and potential mechanisms of different combined modes of icotinib plus pemetrexed in EGFR-mutant lung adenocarcinoma ...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12818

    authors: Cui J,Zhang Y,Su D,Li T,Li Y

    更新日期:2018-09-01 00:00:00

  • Predictors of survival in patients who underwent video-assisted thoracic surgery talc pleurodesis for malignant pleural effusion.

    abstract:BACKGROUND:Patients with malignant pleural effusion have a limited life expectancy. An increase in pleural and oncological treatment options and more accurate prognostic evaluation may help individualize treatment strategies. The aim of this study was to identify the prognostic indicators of overall survival (OS) after...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12354

    authors: Yoon DW,Cho JH,Choi YS,Kim J,Kim HK,Zo JI,Shim YM

    更新日期:2016-07-01 00:00:00

  • Fistula to the native esophagus after pharyngogastrostomy for malignant disease: A rare phenomenon in esophageal surgery.

    abstract::This article features the case study of a 32-year-old female patient who had undergone surgery to remove a cervical spine tumor and who later developed cervical esophagus necrosis secondary to the erosion caused by an osteosynthesis 13 years after her prosthetic cervical surgery. Barium swallow did not show anything a...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/j.1759-7714.2012.00112.x

    authors: Hernández Hernández JR,Navarro Barlés G,López-Tomassetti Fernández EM,Vega Benítez V,Núñez Jorge V

    更新日期:2013-02-01 00:00:00

  • Osimertinib-induced severe interstitial lung disease: A case report.

    abstract::Lung cancer is globally one of the leading causes of malignant tumor-related mortality and ranks as having the highest incidence found in men and second in women. Osimertinib is a drug used to target lung cancer but its toxicity is not fully understood. Here we present a case of lung adenocarcinoma in a 78-year-old ma...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.13127

    authors: Fan M,Mo T,Shen L,Yang L

    更新日期:2019-07-01 00:00:00